RxDoctor Payments Data

Erika Wooldridge, APRN

Nurse Practitioner · Shepherdsville, KYNPI 1235485665

Payments from drug & device makers

$9,302in general payments, 2019–2025

Across 675 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Amgen$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$430
  • Biohaven Pharmaceutical Holding Company Ltd.$410
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$9,290100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,302 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$46,036
Medicare patients
94
Services billed
1,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$74,367
Tresiba Flextouch U-200Insulin Degludec21$61,912
MounjaroTirzepatide37$45,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$36,611
TrulicityDulaglutide20$35,746
FarxigaDapagliflozin Propanediol21$21,176
EliquisApixaban17$18,127
Tresiba Flextouch U-100Insulin Degludec14$13,734
SynjardyEmpagliflozin/Metformin Hcl13$12,073
Repatha SureclickEvolocumab12$9,987
Breo ElliptaFluticasone/Vilanterol16$9,285
TrintellixVortioxetine Hydrobromide12$8,733
Insulin Lispro Kwikpen U-100Insulin Lispro19$4,685
Potassium Chloride92$3,206
Dexlansoprazole DrDexlansoprazole12$3,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$430$81,53557 claims
Novo NordiskOzempic$1,029$74,36750 claims
GSKTrelegy Ellipta, Breo Ellipta$248$45,89673 claims
AstraZenecaFarxiga$116$21,17621 claims
PfizerEliquis$1,080$18,12717 claims
Boehringer IngelheimSynjardy$346$12,07313 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$335$8,73312 claims
AbbVieSynthroid$1,468$2,29139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Shepherdsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →